Pacific Biosciences CEO Mark van Oene sells $30,409 in stock By Investing.com

Mark Van Oene, President & CEO of Pacific Biosciences of California, Inc. (), sold 26,911 shares of common stock on August 17, 2026. The transactions totaled $30,409, with shares sold at a weighted average price of $1.13, ranging from $1.13 to $1.15 per share. The sale comes as PACB stock trades near its 52-week low of $1.07, down 39% year-to-date, according to InvestingPro data. The stock’s current price of $1.14 represents a significant decline from its 52-week high of $2.73.

The sale represents shares automatically disposed of to cover tax withholding obligations associated with the vesting of restricted stock units. Following this transaction, Mr. Van Oene directly holds 2,705,853 shares of Pacific Biosciences of California common stock. For investors seeking deeper insights, InvestingPro offers 7 additional exclusive tips about PACB, plus comprehensive Pro Research Reports covering this and 1,400+ other US equities.

In other recent news, PacBio reported its second-quarter 2026 earnings, revealing a revenue of $39.0 million and an adjusted loss of $0.14 per share. Both figures fell slightly short of Wall Street’s expectations, with revenue missing the forecasted $40.69 million. The company also announced a reduction in its full-year outlook, indicating that achieving cash flow breakeven will take longer than initially anticipated. These developments come as PacBio’s revenue remained essentially flat compared to the previous year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.